HIV i-Base/Treatment Action Group 2013 Pipeline Reportcalls on leaders to get the best HIV, hepatitis C virus (HCV), and tuberculosis drugs, diagnostics, and vaccines to the most people as quickly as possible– Survey shows HIV pipeline healthy, HCV drug development surging,while TB research moves forward much too slowly – – Faster research, approval, and access demanded …
We have repeatedly heard the following statements about multi-drug resistant HIV (MDR-HIV) patients in a host of meetings on treatment access and HIV research: “These patients no longer exist – they’re either dead or have responded to the latest ARVs”; “Only patients who do not adhere to their HIV regimens have MDR-HIV”; and “Our clinic cannot provide expanded access programs (EAPs) due …
WORLD AIDS DAY: Time to Help Victims of HIV Drug Studies and Resistance Read More »
Gilead has completed and released 48-week data from ongoing phase 3 studies of a four-drug fixed dose combination (elvitegravir, cobicistat, tenofovir, and FTC- called QUAD), as it has with studies of the integrase inhibitor elvitegravir and the pharmacokinetic booster cobicistat. QUAD will likely be approved for treatment naive patients after August this year. Results from …
The dolutegravir expanded access program (EAP) has been designed to provide free access to Shionogi-ViiV Healthcare’s investigational integrase inhibitor, dolutegravir (DTG, S/GSK1349572) in an open-label protocol program to adults living with HIV who have documented raltegravir or elvitegravir resistance, who have limited treatment options, and who require DTG to construct a viable antiretroviral regimen for …
By Nelson Vergel, B.S.Ch.E., M.B.A. July 6, 2011 In a previous blog post, I reviewed the current situation for the minority of patients with HIV who have run out of treatment options. Of the HIV medications in development with potential activity against highly resistant HIV (i.e., patients with GSS=0), two may become available within the next …
For Doctors: How You Can Help Your Patients Who Are Running Out of HIV Treatment Options Read More »
Print this page • Back to Web version of article By Nelson Vergel, B.S.Ch.E., M.B.A. May 3, 2011 “Only patients who do not take their medications as prescribed have multidrug resistance.” “Deep salvage patients no longer exist. The ones in that situation are already dead or have responded to the latest HIV antiretrovirals.” “Even if we give …
Is There a Future for HIV-Infected Patients in “Deep Salvage”? Read More »
IAC Summary on New Drugs and New Combinations – How will They Change What We Do? Vienna July 18-23 2010 Joe Eron, Univ of North Carolina This year’s IAC was one of the most exciting and data-filled International AIDS meetings since Vancouver in 1996. The defining presentation of the meeting was the CAPRISA 004 study that …
New Drugs and New Combinations – How will They Change What We Do? Read More »
What am I going to do now, Nelson? Aug 6, 2010 Hi Nelson, I hope all is well. Last year you told me about the trial with ibalizumab at ACRIA and I received the meds for about 1 year. In the beginning of thet trial the virus became undectadable but then it started to go …
I am scared that companies are dropping new HIV medications Jun 17, 2010 Nelson, I emailed you before and you told me there were a few medications in research for people with resistance to all meds. But I just heard that two companies abandoned their research. What does that mean for someone like me who …
HIV Salvage Patients Are Concerned About Recent Pharma Decisions Read More »
Most successful HIV medication combinations require 3 medications that are fully active, but a small portion of long term survivors with long treatment history and accumulated HIV resistance mutations do not have the luxury of constructing a viable regimen to save their lives. Several potent antiretrovirals (ARVs) in the past 4 years have enabled many …
The Forgotten Minority: HIV+ Patients With No Available HIV treatment Options Read More »
